Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $516K | $352K | $6.17K | $0.00 | $0.00 | — | — | — | — | — |
| Revenue growth | — | -31.8% | -98.2% | -100.0% | — | — | — | — | — | — |
| Gross profit | $280K | $179K | $6.17K | $0.00 | $0.00 | — | — | — | — | — |
| Gross margin | 54.3% | 50.9% | 100.0% | — | — | — | — | — | — | — |
| Operating income | -$1.79M | -$4.63M | -$9.02M | -$10.8M | -$11.5M | -$11.5M | -$13.2M | -$10.5M | -$10.8M | -$5.76M |
| Operating margin | -347.5% | -1315.6% | -146080.5% | — | — | — | — | — | — | — |
| Net income | -$2.78M | -$5.38M | -$9.80M | -$13.3M | -$11.7M | -$11.2M | -$13.2M | -$10.1M | -$11.5M | -$7.03M |
| Net margin | -538.3% | -1529.2% | -158669.6% | — | — | — | — | — | — | — |
| EPS (diluted) | -$3.84 | -$1.95 | -$2.17 | -$2.34 | -$0.63 | — | — | -$2,766.85 | -$56.94 | -$8.93 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.32M | -$3.30M | -$7.70M | -$8.59M | -$10.7M | -$11.1M | -$12.8M | -$9.55M | -$7.40M | -$5.18M |
| Capital expenditures | — | $7.86K | $100K | $43.6K | $75.3K | $45.0K | $203K | $33.9K | $16.0K | $17.3K |
| Free cash flow | — | -$3.31M | -$7.80M | -$8.63M | -$10.8M | -$11.2M | -$13.0M | -$9.58M | -$7.42M | -$5.20M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | — | — | $7.23M | $9.46M | $4.89M | $2.83M | $3.23M | $762K |
| Total assets | $491K | $6.12M | $7.22M | $7.18M | $8.76M | $12.9M | $9.27M | $6.75M | $4.45M | $3.85M |
| Total liabilities | $1.38M | $848K | $975K | $2.42M | $1.60M | $2.09M | $2.07M | $1.10M | $1.89M | $1.59M |
| Long-term debt | — | — | — | — | — | $547K | $0.00 | $0.00 | $0.00 | — |
| Shareholders' equity | -$894K | $5.28M | $6.25M | $4.76M | $7.17M | $10.8M | $7.20M | $5.66M | $2.56M | $2.26M |
| Retained earnings | -$12.5M | -$17.9M | -$27.7M | -$45.2M | -$57.3M | -$68.7M | -$81.9M | -$91.9M | -$103M | -$110M |
| Shares (wtd avg diluted) | 723K | 3.92M | 7.42M | 8.42M | 34.0M | 2.13M | 3.17M | 3.64B | 202K | 787K |
Every figure is extracted from ENDRA Life Sciences Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.